Best Practices in the Clinical Management of Patients with BRAF-mutant Metastatic Melanoma

Funding Agency:
Pfizer Inc.

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP. 

Projects that will be considered for Pfizer support will:

• Deliver an update on available clinical data to inform treatment selection for patients with BRAF-mutant metastatic melanoma,

• Increase understanding of treatment side effects and

• Provide strategies for optimal therapy management.

Educational programs including patient case-based discussions will be prioritized. Also, Pfizer is particularly interested in programs held in conjunction with conferences such as the ASCO and ESMO Annual Meetings. 

Grant Application due date: Thursday, 21 April 2022 

Agency Website

Eligibility Requirements

Geographic Scope: United States 

The following entities may apply:  • Medical, dental, nursing, allied health, and/or pharmacy professional schools, • Healthcare institutions (both large and small), • Professional associations and medical societies, • Medical education companies, and • Other entities with a mission related to healthcare professional education and/or healthcare improvement. 



Amount Description

Individual projects requesting up to $100,000 will be considered. The estimated total available budget related to this RFP is $200,000.

Funding Type





Curriculum Development
Medical - Clinical Science

External Deadline

April 21, 2022